POTOMAC, Md.–(BUSINESS WIRE)–IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University’s Center for Research and Training in Artificial Intelligence (“CINFONIA”). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients.
CINFONIA is the Center for Research and Training in Artificial Intelligence led by Professor Pablo Arbelaez at the University of Los Andes Department of Biomedical Engineering. CINFONIA integrates academic excellence, ethical principles, and responsible research to fulfill its mission of transforming the world with Artificial Intelligence for the benefit of humanity.
IGC Pharma and CINFONIA jointly intend to develop and train deep learning algorithms based on state-of-the- art transformer architectures to predict the temporal progression of approximately 1,500 physiological and psychological variables for each patient enrolled in the IGC-AD1 Phase 2 clinical trial.
These variables encompass neuropsychiatric scales, blood pressure, diet, and more intricate elements such as genetic markers and over 100 other biomarkers. The team has become implementing a deep learning algorithm to develop an adversary-based optimization methodology to enable the interpretation of non-linear relationships between these input variables and treatment outcomes, like efficacy and adverse events. The strategic integration of AI is an essential initiative for IGC Pharma as the Company is pursuing five assets developed to target Alzheimer’s disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, which are in different stages of development.
Ram Mukunda, CEO of IGC Pharma, commented, “Often Alzheimer’s patients face years of uncertainty and delayed definitive diagnosis, potentially resulting in the worsening of their condition. The implications of AI integration are profound, as it can help reduce risk in costly clinical trials and potentially get medicine to Alzheimer’s patients faster. We believe this partnership provides IGC Pharma with a competitive advantage in the pharmaceutical industry as implementing AI algorithms may enable us to identify and understand previously unknown patterns in data sets. We eagerly anticipate showcasing our strategic approach at Biotech Showcase 2024 during JP Morgan Healthcare Week, spotlighting IGC Pharma’s strides in AI development.”
Professor Pablo Arbelaez, Director of CINFONIA, commented, “We look forward to collaborating with IGC Pharma on analyzing data from the Phase 2 IGC-AD1 trial. We believe that deep learning algorithms can potentially reveal hidden relationships in clinical trial data that cannot be identified through manual analysis alone. In line with our mission to promote socially responsible research with high social impact, this partnership can potentially improve the treatment efficacy of IGC-AD1 and provide relief to millions of people with Alzheimer’s disease.”
Professor Arbelaez received his PhD from the Université Paris-Dauphine in 2005 and was an AI- Researcher at the University of California (Berkeley) from 2007-2014. He has extensive experience using AI in medicine, biology, and computer vision. He was recognized with the AI 2000 Most Influential Scholar Award Honorable Mention for his contribution in computer vision placing him among the 100 most influential researchers in his discipline in the last decade.
About IGC Pharma Inc. (dba IGC):
IGC Pharma is pioneering innovative solutions to combat Alzheimer’s disease and related challenges. The IGC Pharma portfolio comprises five assets, all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently in a Phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of Generative AI development, with projects including clinical trials, early detection of Alzheimer’s, and drug interactions with cannabinoids.
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.